Estcourt, L.J., Desborough, M., Brunskill, S.J., Doree, C., Hopewell, S., Murphy, M.F., & Stanworth, S.J. (2016). Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders. Cochrane Database of Systematic Reviews, 3, CD009733.
STUDY PURPOSE: To examine the effectiveness of lysine analogues in the prevention of bleeding related to hematological disorders
TYPE OF STUDY: Systematic review
PHASE OF CARE: Active antitumor treatment
Three studies located have not been concluded but may show promise in future analysis. However, the three studies included in the update of this review compared the lysine analogue to placebo. No significant results related to the risk of bleeding were found. All the studies reported a decrease in platelet transfusions given, but no meta-analysis could be performed.
No certain findings existed following this systematic review. Whether TXA or EACA decrease the risk of bleeding or the use of platelet transfusions, or increase the risk of developing a clot, is unclear. Whether they cause adverse events is also unclear.
At this time, not enough evidence supports the use of TXA and EACA in adult patients with acute leukemia receiving chemotherapy.